Histopathology of acute kidney injury in SD rats induced by three monomer components of Polygoni Multiflori Radix

doi:10.19803/j.1672-8629.20220459

Abstract

Abstract: Objective To study the morphology of acute renal injury caused by three Polygoni Multiflori Radix monomers in SD rats after 14 days of oral administration. Methods Fifty male SD rats were randomly divided into the control group, the 28 mg·kg^-1, 280 mg·kg^-1 and 1 120 mg·kg^-1 dose of emodin-8-O-β-D-glucoside groups, the 6.5 mg·kg^-1, 65 mg·kg^-1 and 650 mg·kg^-1 dose groups of emodin-type monoanthranone and the 6.5 mg·kg^-1, 65 mg·kg^-1 and 650 mg·kg^-1dose groups of physcion. All doses of emodin-8-O-β-D-glucoside, emodin-type monoanthranone and physcion were administered orally for 14 days, respectively. After administration, the animals were anesthetized and necropsied, the kidneys were examined for macroscopic observation and weighed before the fixed kidneys were subjected to section preparation and histopathological examination. Results Macroscopic observation showed white nodules in bilateral kidneys of one rat in the 650 mg·kg^-1dose group of emodin-type monoanthranone. There were no gross lesions in SD rats in the three dose groups of emodin-8-O-β-D-glucoside, the 6.5 mg·kg^-1, 65 mg·kg^-1 dose groups of emodin-type monoanthranone, or in the three dose groups of physcion. Compared with the control group, there were no statistically significant differences in the absolute kidney weight or organ/body weight ratio of emodin-8-O-β-D-glucoside, emodin-type monoanthranone and physcion in each dose group (P >0.05). Microscopic observation showed that emodin-8-O-β-D-glucoside could cause the formation of tubular hyaline droplets, emodin-type monoanthranone could induce tubular pigmentation and aggravate tubular basophilia, and that physcion did not cause obvious injury to the kidney. Conclusion Emodin-8-O-β-D-glucoside and emodin-type monoanthranone can lead to morphological changes in the kidney of SD rats, but physcion does not.

Key words: monomer components of Polygoni Multiflori Radix, emodin-8-O-β-D-glucoside, emodin-type monoanthranone, physcion, rat, kidney toxicity, morphological characteristcs

CLC Number:

R994.1

HUO Guitao, WEN Hairuo, YANG Yanwei, QIN Chao, WANG Qi, MA Shuangcheng. Histopathology of acute kidney injury in SD rats induced by three monomer components of Polygoni Multiflori Radix[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1303-1308.

References

[1] LIN L, NI B, LIN H, et al.Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: a review[J]. J Ethnopharmacol, 2015,159: 158-183.
[2] SONG L, WANG Q, BI YN, et al.Study on liver and kidney toxicity of 4 components of Polygoni Multifori radix on mice after intragastric administration for 14 days[J]. Chin J Pharmacov, 2018, 15(9): 513-517.
[3] Center for Drug Reevaluation, NMPA. The UK MHRA warns of liver damage associated with polygonum multiflorum[J]. Chin J Pharmacov, 2006, 3(5): 313-314.
[4] WANG Q, YANG JB, WANG Y, et al.Effects of Polygonum multiflorum extract on rat kidneys based on transporters[J]. Chin J Pharmacov,2022,19(6): 626-629.
[5] WANG Q, WEN HR, YANG JB, et al.Study on the components of Polygonum multiflorum aqueous extract in rats after long-term administration[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(6): 620-625.
[6] WANG Q, ZHANG QH, WEN HR, et al.Study on potential hepatotoxicity of main monomers of Polygonum multiflorum based on liver micro-tissue[J]. Chin J Chin Mater Med, 2020, 45(12): 2954-2959.
[7] Chinese Pharmacopoeia Commission.Pharmacopoeia of People’s Republic of China. Volume I(中华人民共和国药典一部,2020年版)[M]. Beijing: China Medical Science Press, 2020.
[8] LUO DQ, LIU Y, WANG GH, et al.Quality analysis of Polygonum multiflorum and its preparation[J]. Journal of Chinese Medicinal Materials,2016, 39(10):2422-2425.
[9] DAN M, LIU D, HUANG SJ, et al.Study the hepatotoxicity of monoanthranone with emodin-type using in vitro 3D liver model[J]. Chin J New Drug, 2019, 28(11):1312-1317.
[10] WANG Q, WANG YD, YANG JB, et al.Study on hepatotoxicity of emodin-8-O-β-D- glucoside and its metabolites[J]. Chin J New Drug, 2020, 29(16):1856-1862.
[11] National Toxicology Program.NTP toxicology and carcinogenesis studies of emodin (CAS NO. 518-82-1) feed studies in F344/N rats and B6C3F1 mice[J]. Natl Toxicol Program Tech Rep Ser,2001, 493:1-278.
[12] HUO GT, WANG YN, LYU JJ, et al.Chronic toxicity study of emodin monomer in Kunming mice by ig administration[J].Drug Eval Res, 2021, 44(7):1425-1433.
[13] FENG X, FANG SN, GAO YX, et al.Current research situation of nephrotoxicity of Chinese herbal medicine[J]. Chin J Chin Mater Med, 2018, 43(3): 417-424.
[14] WEN HR, YAN YJ, SONG J, et al.Study on in vitro and in vivo genotoxicity of emodin-8-O-β-D-glucoside[J]. China Pharmacy, 2020, 31(1):18-13.
[15] LI KM, SUN XC.Collection and analysis of the data of plants containing emodin-8-O-β-D-glucopyranoside in China[J]. Chin J New Drug, 2016, 25(24): 2787-2792.
[16] MU MJ, LI Y, LI CG, et al.Simultaneous determination of two anthraquinone glucosides in polygonum multiflorum based on UPLC[J]. J Dali Univ, 2018, 36(12): 57-61.
[17] ZHANG LY, JIANG ZZ, PU CH, et al.Six-month oral toxicity study of total anthraquinone in radix et rhizoma rhei in SD rats[J]. Chin J Biochem Pharm, 2004, 24(4): 206-209.
[18] HUANG WY, LI YQ, JIANG Q, et al.Apoptosis mechanism of emodin on renal toxicity in mice[J].Chin J Exp Tradit Med Form, 2019, 25(11): 42-47.
[19] LI YQ, HUANG WY, LIANG YS, et al.Mechanism of nephrotoxicity of aloe emodin in mice[J]. Chin J Exp Tradit Med Form, 2019, 25(11): 48-53.
[20] HU YF, HUANG WY, LI YQ, et al.Mechanism of rhein on renal toxicity of mice[J]. Chin J Exp Tradit Med Form, 2019, 25(11): 54-59.
[21] FRAZIER KS, SEELY JC, HARD GC, et al.Proliferative and nonproliferative lesions of the rat and mouse urinary system[J]. Toxicol Pathol, 2012, 40(4 Suppl): 14S-86S.
[22] YANG JB, TIAN JY, DAI Z, et al.α-Glucosidase inhibitors extracted from the roots of Polygonummu ltiflorum Thunb.[J]. Fitoterapia, 2017,117: 65-70.
[23] YANG JB, WANG Q, WANG XT, et al.Difference analysis of chemical composition of Polygoni Multiflori Radix and Polygoni Multiflori Radix preparata based on plant metabonomics[J]. Chin J Pharmacov, 2022, 19(6): 615-619
[24] YANG JB, LI WF, LIU Y, et al.Acute toxicity screening of different extractions, components and constituents of Polygonum multiflorum thunb. on zebrafish (danio rerio) embryos in vivo[J]. Biomed Pharmacother, 2018, 99: 205-213.
[25] LI HY, YANG JB, LI WF, et al.In vivo hepatotoxicity screening of different extracts, components, and constituents of Polygoni multiflori Thunb. in zebrafish (danio rerio) larvae[J]. Biomed Pharmacother, 2020, 131: 110524.
[26] LOCATELLI M, EPIFANO F, GENOVESE S, et al.Anthraquinone profile, antioxidant and antimicrobial properties of bark extracts of Rhamnus catharticus and R. orbiculatus[J]. Nat Prod Commun, 2011, 6(9):1275-1280
[27] PAN XP, WANG C, ZHANG T.Physcion synergistically enhances the cytotoxicity of sorafenib in hepatocellular carcinoma[J]. Anat Rec (Hoboken), 2019, 302(12): 2171-2177.
[28] ZHANG LY, SU WH, XIONG Y, et al.Protective effect of physcione on acute liver in rats[J]. Chin J Prim Med Pharm, 2007, 12(14): 2014-2015.
[29] WANG RJ, YANG Y, BAI T.Effect of physcion on SIRT1-AMPK pathway in alcoholic liver injury[J]. Chin Pharmacol Bull, 2020, 36(11):1557-1562.
[30] LI JF, WANG RJ, ZHANG YX, et al.Effect of physcion on alleviating drug-induced liver injury through HMGB1- NLRP3 signaling pathway[J]. China Tradit Herb Drugs, 2022, 53(7): 2095-2102.
[31] THOMAS J, ZIMMERMAN B, HARDISTY JF.Occurrence of spontaneous amphophilic-vacuolar renal tubule tumors in Sprague-Dawley rats from subchronic toxicity studies[J]. Toxicol Pathol, 2013, 41(6): 866-871.
[32] HARD GC, SEELY JC, KISSLING GE, et al.Spontaneous occurrence of a distinctive renal tubule tumor phenotype in rat carcinogenicity studies conducted by the national toxicology program[J]. Toxicol Pathol, 2008,36(3):388-396.
[33] ADLEY BP, SMITH ND, NAYAR R, et al.Birt-Hogg-Dubé syndrome: clinicopathologic findings and genetic alterations[J]. Arch Pathol Lab Med, 2006,130(12):1865-1870.